Preoperative Dose Painting IMRT Chemoradiation to 56 Gy in Esophageal Cancer Doubles Pathologic Complete Response Rate Without Increasing Toxicity

Author(s):  
R. Shridhar ◽  
M.D. Chuong ◽  
J. Weber ◽  
K. Almhanna ◽  
K.L. Meredith ◽  
...  
Oncotarget ◽  
2018 ◽  
Vol 9 (41) ◽  
pp. 26406-26416 ◽  
Author(s):  
Angela Santonja ◽  
Alfonso Sánchez-Muñoz ◽  
Ana Lluch ◽  
Maria Rosario Chica-Parrado ◽  
Joan Albanell ◽  
...  

2020 ◽  
Vol 16 (30) ◽  
pp. 2411-2420
Author(s):  
Zhigang Yuan ◽  
Marissa Frazer ◽  
Kamran A Ahmed ◽  
Syeda Mahrukh Hussnain Naqvi ◽  
Michael J Schell ◽  
...  

Aim: Genomic-based risk stratification to personalize radiation dose in rectal cancer. Patients & methods: We modeled genomic-based radiation dose response using the previously validated radiosensitivity index (RSI) and the clinically actionable genomic-adjusted radiation dose. Results: RSI of rectal cancer ranged from 0.19 to 0.81 in a bimodal distribution. A pathologic complete response rate of 21% was achieved in tumors with an RSI <0.31 at a minimal genomic-adjusted radiation dose of 29.76 when modeling RxRSI to the commonly prescribed physical dose of 50 Gy. RxRSI-based dose escalation to 55 Gy in tumors with an RSI of 0.31–0.34 could increase pathologic complete response by 10%. Conclusion: This study provides a theoretical platform for development of an RxRSI-based prospective trial in rectal cancer.


Sign in / Sign up

Export Citation Format

Share Document